Q-Line Biotech NSE SME IPO review

The company is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables.
It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments.
As the company has no listed peers, it is trying to extract fancy price for its IPO.
Based on its overall financial data, the issue appears fully priced.
Well-informed investors may park moderate funds for long term.

About Company

Q-Line Biotech Ltd. (QBL) is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs since 2013 directly or through its distributor/s majorly to diagnostic service providers, hospitals and medical colleges.

The company has established its brands over a period of 12 years through its experience, R & D, manufacturing capabilities and quality assurance. The core segments of operations of the Company in IVD Industry include Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids).

QBL’s key manufacturing segments include indigenous manufacturing of reagents including Clinical Chemistry, Haematology, Immunodiagnostics, Molecular Diagnostics and Others (POC Devices & Rapids) and supplying/ manufacturing of in-vitro diagnostics (IVD), Pathology equipment’s & devices. Further during the Covid-19 pandemic, the company diversified its focus and with the technical collaboration of third-party institutes and through its own R&D team developed a range of Covid testing kits viz. RT-PCR Kits, RNA Extraction Kits, VTM Kits etc.

It is research driven company engaged in developing and manufacturing a wide range of reagents formulations used across various IVD and diagnostic needs. The company leverages its R&D capabilities to develop and manufacture a portfolio of differentiated reagent formulations /products. Further, for its certain Class of Reagent & equipment’s and devices manufacturing business, the company has entered into technical collaboration with certain international companies. Under the agreement terms, it undertakes the manufacturing of these Reagent and equipment’s and devices as per the technical collaboration and specifications provided by the partners or companies.

With the help of these collaborations the equipment and devices adhere to strict quality control, international standards and certifications. As of March 31, 2026, the company employed 19 personnel at R&D laboratories, which constituted 5.25% of its total permanent employee strength. As of March 31, 2026, it had 362 employees on its payroll and additional 223 contract employees in various departments.

Issue Details / Capital History

The company is coming out with its maiden book building route IPO of 6253200 equity shares of Rs. 10 each to mobilize Rs. 214.48 cr. at the upper cap. The company has announced a price band of Rs. 326 - Rs. 343 per share. The minimum application to be made is for 800 shares and in multiples of 400 shares thereon, thereafter. The IPO opens for subscription on May 21, 2026, and will close on May 25, 2026. The IPO constitute 26.81% of the post-IPO paid-up capital of the company. The shares will be listed on NSE SME Emerge. From the net proceeds of the IPO, it will utilize Rs. 93.50 cr. for working capital, Rs. 90.00 cr. for repayment/prepayment of certain borrowings, and the rest for general corporate purposes.

The company raised Rs. 27.44 cr. in a pre-IPO placement of 800000 shares in May 2026, at Rs. 343 per share.

The IPO is jointly lead managed by Hem Securities Ltd., and Share India Capital Services Pvt. Ltd., Purva Sharegistry (India) Pvt. Ltd., is the registrar to the issue. HEM group’s Hem Finlease Pvt. Ltd., is the market maker as well as a syndicate member.

The company has issued initial equity capital at par value. It raised further equity shares in the price range of Rs. 125 – Rs. 417 between March 2019 and May 2026. It has also issued bonus shares in the ratio of 2 for 1 in March 2016, and 9 for 1 in August 2025. The average cost of acquisition of shares by the promoters is Rs. 0.00, Rs. 0.04, and Rs. 18.34 per share.

Post-IPO, company’s current paid-up equity capital of Rs. 17.07 cr. will stand enhanced to Rs. 23.33 cr. Based on the upper band of the IPO pricing, the company is looking for a market cap of Rs. 800.16 cr.

IPO Lead Managers & Registrar

Financial Performance

On the financial performance front, for the last three fiscals, the company has (on a consolidated basis) posted total income/ net profit, of Rs. 184.81 cr. / Rs. 32.10 cr. (FY23), Rs. 206.45 cr. / Rs. 34.44 cr. (FY24), Rs. 322.58 cr. / Rs. 28.13 cr. (FY25). For 9M of FY26 ended on December 31, 2025, it earned a net profit of Rs. 38.69 cr. on a total income of Rs. 236.50 cr. Though it posted growth in its top lines for the reported periods, its bottom line posted inconsistency. For FY25, it posted lower net profit of Rs. 28.13 cr., and for 9M-FY26, though the top line is Rs, 236.50 cr. it posted bumper profit of Rs. 38.69 cr. in a pre-IPO period, that not only raise eyebrows, but also concern over its sustainability going forward. Despite higher other income for FY25, it marked lower net following extra-ordinary item of Rs. 16.97 cr. Its contingent liability stood at Rs. 61.64 cr. as of December 31, 2025, that raises alarm. Its overall borrowings of Rs. 242.57 cr. as of December 31, 2025, raise concern.

For the last two fiscals, the company has reported an average EPS of Rs. 25.00, and an average RoNW of 23.17%. The issue is priced at a P/BV of 2.44 based on its NAV of Rs. 140.81 per share as of December 31, 2025, but its post-IPO NAV data is missing from the offer documents.

If we attribute FY26 super earnings to its post-IPO fully diluted paid-up equity capital, then the asking price is at a P/E of 15.51, and based on FY25 earnings, the P/E stands at 28.44. The issue appears fully priced, based on its bumper earnings for 9M-FY26, which may not be sustained.

For the reported periods, the company has posted PAT margins of 17.56% (FY23), 16.92% (FY24), 8.97% (FY25), 16.65% (9M-FY26), and RoCE margins of 22.14%, 19.25%, 17.66%, 13.32%, respectively, for referred periods.

All amounts in Indian Rupees crores

Period Ended	Revenue	Expense	PAT	Assets
2023	₹184.81	₹154.97	₹32.10	₹251.58
2024	₹206.45	₹175.85	₹34.44	₹339.25
2025	₹322.58	₹261.43	₹28.13	₹455.49
Dec 2025	₹236.50	₹186.96	₹38.69	₹561.34

Dividend Policy

The company has not paid any dividends for the reported periods of the offer document. It will adopt a prudent dividend policy, based on its financial performance and future prospects.

Comparison with Listed Peers - for Fiscal 2025

As per the offer document, the company has no listed peers to compare with.

Name of the Company	Face Value (₹)	EPS basic (₹)	EPS Diluted (₹)	RONW (%)	P/E Ratio	NAV (₹)
Powerica Limited	5	15.26	15.26	15.37 %	24.45	99.76
Listed Peers
Cummins India Limited	2	72.15	72.15	26.45%	64.13	272.78
Kirloskar Oil Engines Limited	2	33.71	33.60	15.85%	43.24	212.60
NTPC Green Energy Limited	10	0.67	0.67	2.58%	129.40	21.88
Acme Solar Holdings Limited	2	4.55	4.53	5.59%	50.74	74.54
Adani Green Energy Limited	10	8.37	8.37	11.90%	101.53	76.62

Disclaimer: Above table shows earnings and P/E ratio as of 2025-26

Merchant Banker's Track Record

The two merchant bankers associated with this issue have handled 79 issues in the past three years, out of which 8 issues closed below the issue price on listing date.

Conclusion - Apply for medium to long term

QBL is engaged in the business of developing, manufacturing and marketing of diverse range of reagents and consumables. It posted growth in its top lines for the reported periods, but suffered a setback for FY25 in bottom line following accounting adjustments. As the company has no listed peers, it is trying to extract fancy price for its IPO. Based on its overall financial data, the issue appears fully priced. Well-informed investors may park moderate funds for long term.

Dilip Davda is a veteran financial journalist associated with the Indian stock market since 1978. He has been contributing to print and electronic media on capital markets, insurance, and finance since 1985.

He is widely recognized for reviewing public issues and non-convertible debentures (NCDs) in the primary market. Drawing on over three decades of market experience and close interaction with merchant bankers, his reviews focus on detailed fundamental and financial analysis of companies, with a special emphasis on SME public issues.

Disclaimer: The information provided herein is solely for educational and informational purposes and does not constitute an offer, solicitation, or recommendation to buy or sell any securities. Readers are advised to consult a qualified financial advisor before making any investment decisions. Investments in the securities market are subject to market risks. The author does not intend to invest in the securities discussed.

FAQ Accordion

Q-Line Biotech IPO FAQs

1. What is Q-Line Biotech IPO? ⌄

Q-Line Biotech IPO is SME IPO. The company is going to raise ₹214 Crores via IPO. The issue is priced at ₹326 to ₹343 per equity share. The IPO is to be listed on NSE SME.

2. When Q-Line Biotech IPO will open for subscription? ⌄

The IPO is to open on May 21, 2026 for QIB, NII, and Retail Investors. The IPO will close on May 25,2026.

3. What is Q-Line Biotech IPO Investors Portion? ⌄

The investors’ portion for QIB is 50%, NII is 15%, and Retail is 35%.

4. How to Apply the Q-Line Biotech IPO? ⌄

You can apply for Q-Line Biotech IPO via ASBA online via your bank account. You can also apply for ASBA online via UPI through your stock brokers. You can also apply via your stock brokers by filling up the offline form.

5. What is Q-Line Biotech IPO Issue Size? ⌄

Q-Line Biotech IPO issue size is ₹214 crores.

6. What is Q-Line Biotech IPO Price Band? ⌄

Q-Line Biotech IPO Price Band is ₹326 to ₹343.

7. What is Q-Line Biotech IPO Lot Size? ⌄

The minimum bid is 800 Shares with ₹2,74,400 amount.

8. What is the Q-Line Biotech IPO Allotment Date? ⌄

Q-Line Biotech IPO allotment date is May 26,2026.

9. What is the Q-Line Biotech IPO Listing Date? ⌄

Q-Line Biotech IPO listing date is May 29, 2026. The IPO is to list on NSE SME.

Bharat Coking Coal (BCCL) IPO Review & Investor Guide

By Jagat Joshi
January 10, 2026

Bharat Coking Coal (BCCL) IPO opens on January 9, 2026, and closes on January 13, 2026. The Bharat Coking Coal (BCCL) IPO price band is set between ₹21 to ₹23 per share, with a face value of ₹10 each. According to the RHP, the company plans to raise approximately ₹1,071 crores through an IPO.

For investors, deciding whether the Bharat Coking Coal (BCCL) IPO is a good investment or not can be quite challenging. If you are unsure and still thinking about whether to apply or skip this IPO, don’t worry. In this article, we present the top key factors and a detailed review of the Bharat Coking Coal (BCCL) IPO. This will help you analyze the strengths, risks, and financial details of the Bharat Coking Coal (BCCL) IPO, enabling you to make a more informed investment decision.

About Company

Founded in 1972, Bharat Coking Coal is India’s largest coking coal, non-coking coal, and washed coal producer, holding 58.50% of the market share of domestic coal production. BCCL consists of 34 operating miles of coal, serving the steel and power industries. The company runs its business with mines located at Jharia, Jharkhand, and Raniganj, West Bengal coalfields.

In FY25, the company’s coal production increased to 40.50 million tonnes. Furthermore, in FY25, the company has produced nearly 58.5% of India’s domestic coking coal. They operate their business with open and underground mines, coal washeries, reopening discontinued underground mines, and coal washeries that are stopped or lying unused for some time.

Strengths

Bharat Coking Coal Limited is the largest producer of coking coal in India. As of April 1, 2024, the company has 791 million tonnes of coal resources, making it the primary source of coking coal production in India.

The demand for coking coal in India is expected to rise significantly, increasing from 67 million metric tonnes in FY25 to 138 million metric tonnes by FY35.

The strong parentage of Coal India Limited gives it a strategic technological and financial strength for sustainable growth.

The company is almost debt-free.

Weaknesses

The company has contingent liabilities of ₹4,930 crore, representing potential future obligations that may arise in the future, can affect the business, cash flow, and financial condition.

BCCL generates 87% of its revenue from its top 10 customers, and losing any of its key customers can adversely affect the business, financial condition, and cash flow.

The IPO is entirely an Offer for Sale (OFS) with no fresh issue component, which means the proceeds will go to exiting shareholders and will not be used for the company’s growth

Other income of ₹598 crore comes from non-core activities.

Debtor days have increased from 39.1 to 48.2 days.

Bharat Coking Coal (BCCL) IPO Review

Reviewer	Recommendation
IPO Watch	May Apply
Ashika Research
Axis Capital
Canara Bank Securities Ltd	Apply
Capital Market	May Apply
ICICI Direct
Marwadi Shares and Finance Ltd	Apply
SBICAP Securities Limited	Apply
Sushil Finance Ltd	Apply
Swastika Investmart Ltd	Apply

Bharat Coking Coal (BCCL) IPO Details

IPO Open Date:	January 9, 2026
IPO Close Date:	January 13, 2026
Face Value:	₹10 Per Equity Share
IPO Price Band:	₹21 to ₹23 Per Share
Issue Size:	₹1,071 Crores
Offer-for-Sale	Up to 46,57,00,000 Equity Shares
Registrar	Kfin Technologies Ltd.
IPO Lead Managers	IDBI Capital Markets Services Ltd. ICICI Securities Ltd.
Basis of Allotment	January 14, 2026
IPO Listing Date:	January 16, 2026
Listing	BSE, NSE

Financial Performance Trend Details

Particulars (in ₹ Cr)	30 Sep 2025	31 Mar 2025	31 Mar 2024
Total Income	6,311.51	14,401.63	14,652.53
EBITDA	459.93	2,356.06	2,493.89
EBITDA Margin	7.29%	16.36%	17.02%
PAT	123.88	1,240.19	1,564.46
PAT Margin	1.96%	8.61%	10.68%
Net Worth	5,830.89	6,551.23	5,355.47
Reserves & Surplus	1,006.52	1,805.73	664.72
Borrowings	1,559.13

Key Performance Indicator

KPI	Values
RoNW	20.83%
ROCE	30.13%
PAT	8.61%
Price to Book Value	1.63
EBITDA Margin	16.36%
Market Cap	₹10,711.10 Cr.

Peer Comparison with the Company

Name of the Company	Face Value(₹)	Basic EPS (₹)	Diluted EPS(₹)	RONW (%)	P/E Ratio	NAV(₹)
Bharat Coking Coal Limited (BCCL)	10	2.66	2.66	20.83%	8.65	14.07
Global Listed Peers
Alpha Metallurgical Resources, Inc	$0.01	1,233.78	1,222.65	11.48%	14.87	11,182.10
Warrior Met Coal, Inc.	$0.01	410.12	410.12	12.82%	19.44	3,423.71

Promoters & Track Records, if any

Coal India Limited holds 4,657,000,000 Equity shares, representing 100% of the equity share capital.

Bharat Coking Coal (BCCL) IPO Valuation – Is It Priced Fairly?

At the upper price band of ₹23, Bharat Coking Coal (BCCL) IPO is valued at a P/E of around 8.56x based on its FY25 earnings.

When compared with listed global peers, like Alpha Metallurgical with a P/E ratio of 14.9x and Warrior Met Coal with a P/E ratio of 19.4x, indicating that Bharat Coking Coal (BCCL) is priced below the sector average.

Verdict: The IPO valuation appears reasonable, considering the company’s leadership in India’s coking coal production.

Bharat Coking Coal (BCCL) IPO – Should You Apply or Not?

Bharat Coking Coal (BCCL) IPO benefits from India’s largest coking coal producer with strong industry positioning, steady demand from steel & power industries, and strong parentage of Coal India Limited, which supports long-term stability.

On the risk side, the business remains dependent on its top 10 customers, contingent liabilities, high employee costs, and limited pricing flexibility, which could impact profitability and cash flows.

As of January 9, 2026, the GMP of the Bharat Coking Coal (BCCL) IPO is ₹11, indicating a listing gain of around 45% to 48%. Short-term investors may consider applying for the IPO, supported by PSU backing and positive market sentiment.

Long-term investors must evaluate risks related to cost pressure, high dependence on a few customers, and government control before subscribing to the IPO.

Please note:

Investors are advised to make their own decisions and apply entirely at their own risk. This article uses information from the company’s RHP (Red Herring Prospectus) data and online sources. If you have any queries, kindly contact the IPO Watch Team.

Jagat Joshi

Founder of IPOWatch, brings nearly 15 years of experience in IPO analysis and market research. He provides complete coverage of upcoming IPOs, subscription trends, grey market premiums (GMP), and post-listing performance, along with easy-to-understand reviews, insights, and analysis. In his working journey, he has worked with various platforms and received expertise in stock market analysis and primary markets.